Affinity and Avidity in Antibody-Based Tumor Targeting

Engineered antibody fragments and the rise of single domains

2005 • 1,830 citations

Monoclonal antibody therapy of cancer

2005 • 1,209 citations

Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.

1988 • 703 citations

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

2001 • 599 citations

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

1990 • 567 citations

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

2008 • 526 citations

Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin

2004 • 461 citations

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.

1992 • 397 citations

Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site

1996 • 380 citations

A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

1990 • 343 citations

Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.

1986 • 308 citations

Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using Affinity-driven Selection

1996 • 295 citations

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

2001 • 273 citations

Antibody constructs in cancer therapy

2006 • 265 citations

Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.

1989 • 257 citations

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

1998 • 234 citations

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1998 • 209 citations

High avidity scFv multimers; diabodies and triabodies

1999 • 209 citations

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

1995 • 182 citations

Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis

2003 • 178 citations

An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".

1991 • 170 citations

Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 Diabody

2005 • 167 citations

Fully Human Therapeutic Monoclonal Antibodies

2005 • 159 citations

Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.

2002 • 131 citations

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

2008 • 128 citations

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

2006 • 126 citations

Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases

2007 • 124 citations

Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen

2007 • 120 citations

Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts

2008 • 117 citations

PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5

2006 • 117 citations

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

2000 • 113 citations

The fate of antibodies bound to the surface of tumor cells in vitro.

1992 • 104 citations

Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design

2008 • 103 citations

Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids

2008 • 99 citations

Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers

2006 • 97 citations

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

2008 • 96 citations

Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability

2008 • 90 citations

Novel antibodies as anticancer agents

2007 • 84 citations

High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy

2008 • 59 citations

Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function

2001 • 54 citations

Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model.

2000 • 47 citations

The macroscopic and microscopic pharmacology of monoclonal antibodies

1992 • 32 citations

Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts

1996 • 32 citations

Taking engineered anti-CEA antibodies to the clinic

1999 • 32 citations

Recent advances in the generation of bispecific antibodies for tumor immunotherapy.

2004 • 32 citations

Improving monoclonal antibodies for cancer therapy

2004 • 25 citations

Radioimmunotherapy with engineered antibodies

2004 • 24 citations

Antibody Engineering Principles and Applications

2008 • 21 citations

Radioimmunotherapy with engineered antibodies

2004 • 2 citations